We are currently initiating a trial with inebilizumab in ME/CFS and PCS patients, a monoclonal antibody directed against CD19 on B cells and plasma blasts showing high clinical efficacy in neuromyelitis optica.43 Here, CD19 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.